Since GM-CSF treatment has not been associated with significant adverse effects so far, a large prospective multi-center with standardized GM-CSF administration to sepsis patients with the aim of stratifying patients and disease states is warranted to define a possible role for GM-CSF immunostimulating adjuvant therapy in sepsis management. Here, CSF2 is linked to Sepsis.